Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

The post Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena appeared first on Investor’s Business Daily.